# Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs

> **NCT02597387** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Relapsed DLBCL and PT/NKCLs

## Interventions

- **DRUG:** Mitoxantrone HCL Liposome Injection

## Key facts

- **NCT ID:** NCT02597387
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2018-09
- **Final completion:** 2018-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597387, "Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02597387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*